We administered CS-514, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, alone and in combination with cholestyramine to heterozygous Watanabe heritable hyperlipidemic rabbits. This rabbit model for heterozygous familial hypercholesterolemia has hepatic low-density lipoprotein receptors that are assumed to be half as many as in normal rabbits. CS-514 alone lowered plasma low-density lipoprotein cholesterol levels by 50%, and in combination with cholestyramine, it lowered levels by 80%. The membrane-binding assay showed these drugs caused 1.5-and 1.8-fold increases in the number of hepatic low-density lipoprotein receptors, respectively. We also measured the amount of mRNA for low-density lipoprotein receptor by S1 nuclease protection assay in the same livers as above. These drugs induced mutant mRNA for the low-density lipoprotein receptor, which has an in-flame deletion of 12 nucleotides, as well as normal receptor mRNA. CS-514 alone produced a 1.8-fold increase in the amount of mRNA for the normal receptor and a 2.3-fold increase for the mutant mRNA, whereas CS-514 in combination with cholestyramine produced 1.9-and 3.1-fold increases, respectively. We conclude that CS-514 induces mRNA for the low-density lipoprotein receptor, subsequently increasing the receptor protein in the liver, and then reduces the levels of plasma cholesterol, and that the induction is augmented when the drug is administered in combination with cholestyramine. (Circulation 1989;79:1084-1090 P atients with hypercholesterolemia, especially with high levels of plasma low-density lipoprotein (LDL) cholesterol, are known to be at increased risk for coronary heart disease. LDL carries the bulk of cholesterol in plasma and is mostly catabolized through a hepatic LDL receptor.1 The decrease in the number of hepatic LDL receptors raises the level of LDL cholesterol in blood, causing both the overproduction and the underca-
tabolism of LDL.2-3 Theoretically, inhibition of de novo cholesterol synthesis in the liver and bile acids reabsorption from the intestine cause the liver to demand more LDL uptake and thus stimulate the production of hepatic LDL receptors. [3] [4] [5] In patients with heterozygous familial hypercholesterolemia (FH), whose hapatic LDL receptors are assumed to be half as many as those of healthy humans because of an inborn error,6 the elevated levels of plasma LDL cholesterol may be reduced by inducing hepatic LDL receptors maximally. Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, which is the rate-limiting enzyme of de novo See p 1146 cholesterol synthesis, have been available. Previous studies of patients with heterozygous FH have shown the reduction of plasma LDL cholesterol levels by such drugs,7-9 and the additive effects of bile acid sequestrant resins were observed. [10] [11] [12] In this study, we used the heterozygous Watanabe heritable hyperlipidemic (WHHL) rabbit as an animal model for heterozygous FH to investigate the hepatic LDL receptor activity.313, 14 We administered to heterozygous WHHL rabbits, CS-514, 15 an inhibitor of HMG-CoA reductase alone and in combination with cholestyramine, and we studied the induction of hepatic LDL receptor protein and mRNA for LDL receptors.
Methods Materials CS-514 was kindly provided by Sankyo (Tokyo, Japan). A chow diet supplemented with 2% cholestyramine was obtained from Oriental Yeast (Tokyo, Japan). 1251 was purchased from New England Nuclear (Boston, Massachusetts) and "2P-labeled nucleotides (3,000 Ci/mmol) were from Amersham (Arlington Heights, Illinois). Si nuclease was from Bethesda Research Laboratories (Gaithersburg, Maryland) and Klenow fragment of Escherichia coli DNA polymerase was from Boehringer Mannheim (Mannheim, FRG). M13 universal sequence primer (17 bases) was obtained from Pharmacia (Uppsala, Sweden).
All other chemicals were of reagent grade.
Rabbits
Japanese white rabbits were purchased from Shimizu Laboratories (Kyoto, Japan). Heterozygous WHHL rabbits were raised in Kyoto by mating pairs of male homozygous WHHL rabbits and female heterozygous WHHL rabbits. Heterozygous WHHL rabbits were distinguished from homozygous WHHL rabbits by their plasma cholesterol levels.
Drug Administration
CS-514 was dissolved in water (50 mg/ml) and was administered orally once a day at a dose of 50 mg/kg body wt. A chow diet supplemented with 2% cholestyramine was also administered 100 g/day (2 g cholestyramine/day). Control rabbits were fed the same chow without cholestyramine, and the same volume of water was administered but without CS-514. Plasma cholesterol levels were measured before and at the end of the drug administration. Rabbits were killed at the end of the study period so that their hepatic LDL receptor activity could be estimated.
Membrane Binding Assay
The liver tissues were homogenized with a Polytron homogenizer (Kinematica, Luzern, Switzerland) and membranes (fraction sedimenting between 8,000 and 100,000g) were prepared as described. Membrane pellets were stored in liquid nitrogen and were resuspended in buffer A (50 mM NaCl/1 mM CaCl2/20 mM Tris-HCl/1 mM phenanthroline/1 mM phenylmethylsulfonyl fluoride (PMSF)/0.5 mM leupeptin, pH 8) by being flushed through 22-and 25-gauge needles five times each. Membrane suspensions were sonicated for 45 seconds and diluted with buffer A to a protein concentration of 10 mg/ ml. The liver membrane (100 ,g protein) and the indicated amount of`MI-labeled LDL were incubated in 80 ,ll buffer B (20 mM NaCl/0.63 mM CaClJ50 mM Tris-HCl/1 mM phenanthroline/1 mM PMSF/0.5 mM leupeptin, pH 8) for 60 minutes at 00 C in the presence or absence of 5 mM ethylenediaminetetraacetic acid (EDTA). Membrane-bound 125I-labeled LDL was separated by ultracentrifugation at 100,000g in a Beckman 42.2 rotor (Fullerton, California) and counted in a gamma counter. LDL (1.019-1.063 g/ml) was isolated by ultracentrifugation from plasma obtained from fasting normal Japanese white rabbits with the anticoagulant EDTA, and it was radioiodinated with iodine monochloride to a specific activity of about 250 cpm/ng protein. EDTA-sensitive binding was calculated by subtracting the amount of 125I-labeled LDL bound in the presence of EDTA (EDTA-resistant binding) from that bound in the absence of EDTA and was considered to be specific for the LDL receptor.14
Si Nuclease Protection Assay
Total cellular RNA was isolated from liver by guanidinium isothiocyanate-cesium chloride method.16
A single-strand uniformly "2P-labeled cDNA probe was prepared as previously described.'7 In brief, an M13 DNA template, which was kindly provided by T. Yamamoto, was prepared by subcloning a 419base-pair Pst 1/Sma I fragment from the coding region of pLDLR-11, a rabbit LDL receptor cDNA, into the Pst I/Sma I site of the M13mp18 vector. This fragment contained the region where 12 nucleotides were deleted in WHHL rabbits. The M13 template was hybridized with a universal sequencing primer 17 nucleotides in length. This primer was then extended by incubation with dTTP, dATP, dGTP, [a-"2P]dCTP, and the Klenow fragment of Escherichia coli DNA polymerase. After EcoR I digestion, the single-strand fragment-was isolated by 7 M urea/ 6% polyacrylamide gel electrophoresis. S1 nuclease protection assay was conducted by the method of Yamamoto et al18 with minor modification. For hybridization, 50 ,g total cellular RNA and the 32P-labeled cDNA probe was incubated at 370 C for 16 hours in a buffer containing 80%(v/v) formamide, 400 mM NaCl, 5 mM EDTA, and 40 mM piperazine-N,N'-bis(2-ethanesulfonic acid) (PIPES) (pH 6.4). RNA-DNA hybrids were then digested with 300 units of SI nuclease for 1 hour at 370 C. Protected fragments were detected by autoradiography after size fractionation on 7 M urea/6% polyacrylamide gel electrophoresis. HinF I-digested plasmid pBR322 DNA fragments were used as size standards. Results were quantified by densitometric scanning.
Other Assays
Protein was determined by the method of Lowry Results Two male heterozygous WHHL rabbits and two male normal Japanese white rabbits were administered CS-514 in combination with cholestyramine for 14 days. Their plasma cholesterol levels before and after the drug administration are shown in Figure 1 . The plasma cholesterol levels of nontreated rabbits used as controls are also indicated. Treatment of CS-514 in combination with cholestyr- amine reduced the levels of total plasma cholesterol by 62% and 69% in heterozygous WHHL and normal rabbits, respectively. The levels of plasma LDL cholesterol were lowered by 84% and 98%, respectively, and high-density lipoprotein (HDL) cholesterol levels were also reduced by 55% and 50%, respectively. Their body weights were not significantly changed, and no difference was found between treated and control rabbits, although normal rabbits were slightly heavier than heterozygous WHHL rabbits (data not shown). EDTA-sensitive binding of' 251-labeled LDL to their liver membranes showed saturation kinetics and was obviously increased in treated rabbits (Figure 2A ). Scatchard analysis showed these drugs caused 2.3-fold (16 vs. 38 ng/mg) and 1.6-fold (57 vs. 86 ng/mg) increases in maximum binding (Bmax) in heterozygous WHHL and normal rabbits, respectively ( Figure 2B ). Their dissociation constant (Kd) values were constant in the four groups above and were about 1.8 ,ug/ml. Adrenal membranes were also prepared from the same rabbits, and their LDL-binding activity was compared at the LDL concentration of 1.5 ,ug protein/ml. In contrast with liver membranes, no difference was found between control and treated rabbits in either of heterozygous VHHL or normal rabbits (Table 1) .
On the basis of preliminary experiments mentioned above, we performed the following experiments. Heterozygous WHHL rabbits were assigned to three groups. One group was treated with CS-514 alone, and the second group was treated with CS-514 in combination with cholestyramine. The third group was used as the control group. Body weights (2.5-3.6 kg) were not significantly different among the three groups above and were not significantly changed during the drug treatment. Their concentration of cholesterol in each plasma lipoprotein fraction is indicated in Table 2 . CS-514 alone produced a 48% reduction in total plasma cholesterol levels, whereas CS-514 in combination with cholestyramine produced a 68% reduction. The LDL cholesterol level decreased by 50% and 80%, respectively, and the HDL cholesterol level decreased by 44% and 58%, respectively.
Binding of 1251-labeled LDL to liver membranes at the ligand concentration of 1.5 ,ug protein/ml was 8.7+2.4 (ng LDL bound/mg membrane) in control rabbits, 12.8+3.0 (1.5-fold increase) in CS-514treated rabbits, and 15.6±3.1 (1.8-fold increase) in rabbits treated with CS-514 and cholestyramine. EDTA-resistant binding, which is considered to be nonspecific, was not significantly different among the above three groups (Table 3) . Figure 3 illustrates the correlation between the total plasma cholesterol levels and the levels of hepatic LDL receptor activity in heterozygous WHHL rabbits from the data described above. An inverse relation can be found between the levels and is more apparent in treated rabbits. The overall correlation coefficient was -0.66. We also quantified the amounts of mRNA for the LDL receptor in livers from three rabbits in each group. For the purpose of separating normal LDL receptor mRNA from the mutant LDL receptor mRNA, which has an in-flame deletion of 12 nucleotides, in heterozygous WHHL rabbits, we took advantage of Si nuclease protection assay. A typical result is shown in Figure 4 . In heterozygous WHHL rabbits, 249-and 158-nucleotide fragments were visible resulting from digestion by single strandspecific S1 nuclease at the site of deletion, in addition to a 419-nucleotide fragment. mRNA for the mutant LDL receptor, as well as mRNA for the normal LDL receptor, was increased in livers of treated heterozygous WHHL rabbits. Densitometric analysis of 419-nucleotide bands showed a 1.8fold increase in the amount of normal hepatic LDL receptor mRNA in CS-514-treated rabbits and a 1.9-fold increase in rabbits treated with CS-514 and cholestyramine, whereas 249-nucleotide bands derived from the mutant LDL receptor mRNA were increased 2.3-fold and 3.1-fold, respectively (Table  4 ). We also measured the amount of mRNA for /8-actin in the samples above by Northern blotting, and we confirmed no significant difference among the three groups (data not shown).
Discussion
The present data are direct evidence that CS-514 raises the level of mRNA for LDL receptors, subsequently increasing the number of LDL receptors, in livers of heterozygous WHHL rabbits and reduces the levels of plasma cholesterol. This effect is augmented when the drug is administered in combination with cholestyramine. Increased hepatic LDL receptors can accelerate the removal of plasma LDL and also decrease the production of LDL by increasing the rapid hepatic uptake of plasma intermediatedensity lipoprotein (IDL) which is the precursor of function in internalizing and degrading LDL or apolipoprotein E-containing lipoproteins, may contribute in reducing the LDL level in plasma when it is fully induced. Ma et a120 reported the induction of mRNA for LDL receptors in livers of homozygous WHHL rabbits treated with mevinolin, an inhibitor of HMG-CoA reductase, and showed the reduction in their plasma cholesterol levels. Their report seems to support our results. Though we cannot readily extend these data to humans, they may explain the variety of cholesterol-lowering effects of these drugs on patients with heterozygous FH who have a variety of mutations of LDL receptor.
We cannot, however, rule out the possibility that mechanisms other than the LDL receptor may contribute to reducing plasma LDL levels. Inhibition of de novo cholesterol synthesis may affect the secretion of very low-density lipoprotein (VLDL) in the liver, which is the major source of plasma IDL and LDL, although previous studies showed no difference in the secretion rate of VLDL between normal and homozygous WHHL rabbits.21 CS-514 also lowered cholesterol levels in all lipoprotein fractions as did mevinolin in experimental animals.20,22 In humans, neither of these drugs reduced HDL cholesterol levels in plasma.7,8 We do not know the precise mechanism accounting for the difference, but two possibilities were postulated previously.20 HDL fractions from lower animal species are more abundant in apolipoprotein E and may therefore be taken up by hepatic LDL receptors. In addition, increased LDL receptors may accelerate the catabolism of VLDL and then reduce the production of HDL, some of whose lipids are derived from lipolized VLDL. 23 CS-514 was shown to be different from mevinolin or compactin in that its inhibitory effect is specific for liver and intestine. 15 Indeed, CS-514 did not induce the LDL receptor activity in the adrenal glands in our study.
Shimada et a124 reported that cultured skin fibroblasts from heterozygous WHHL rabbits internalize and degrade LDL almost to the same degree as those from normal rabbits. The plasma cholesterol levels of heterozygous WHHL rabbits are not remarkably higher than those of normal rabbits when compared with plasma cholesterol levels in humans with heterozygous FH.3 However, heterozygous WHHL rabbits seem to be suitable for the animal model of humans with heterozygous FH whose LDL receptor cannot be measured directly. The present data strongly suggest that the inhibitor of HMG-CoA reductase in combination with bile acid sequestrant resin is beneficial for the treatment of heterozygous FH.
